-
公开(公告)号:EP2346495B1
公开(公告)日:2016-07-20
申请号:EP09740728.2
申请日:2009-10-05
发明人: BECHTOLD, Michael, Karl , PACKHAEUSER, Claudia, Bettina , CAHILL, Julie, Kay , FASTNACHT, Katja, Maren , LIEPOLD, Bernd, Harald , LENNON, Kieran, James , STEITZ, Benedikt
IPC分类号: A61K31/502 , A61K47/32
CPC分类号: A61K31/502 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2095 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/32
摘要: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
摘要翻译: 本发明涉及药物制剂,其包含药物4-固体分散体中的4- [3-(4-环丙烷羰基 - 哌嗪-1-羰基)-4-氟 - 苄基] -2H-酞嗪-1-酮与基质聚合物 其具有低吸湿性和高软化温度,例如共聚维酮。 本发明还涉及由这种制剂提供的药物的每日药物剂量。 此外,本发明涉及使用4- [3-(4-环丙烷羰基 - 哌嗪-1-羰基)-4-氟 - 苄基] -2H的固体分散体中具有低吸湿性和高软化温度的基质聚合物 β-萘啶-1-酮,用于提高药物的生物利用度。
-
公开(公告)号:EP2346495A1
公开(公告)日:2011-07-27
申请号:EP09740728.2
申请日:2009-10-05
发明人: BECHTOLD, Michael, Karl , PACKHAEUSER, Claudia, Bettina , CAHILL, Julie, Kay , FASTNACHT, Katja, Maren , LIEPOLD, Bernd, Harald , LENNON, Kieran, James , STEITZ, Benedikt
CPC分类号: A61K31/502 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2095 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/32
摘要: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
-